title: Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.
abstract: B7-H4 inhibits T-cell activation and is widely expressed by solid neoplasms. We have recently demonstrated that the expression of B7-H4 on the surface of malignant cells in vivo is inducible, and that novel anti-B7-H4 recombinant antibodies can reverse the inhibition of tumor-specific T cells. Thus, antibodies targeting the B7-H4 pathways may extend the survival of cancer patients by restoring T cell-mediated antitumor responses.
authors.affiliation: Department of Oncology; Ludwig Cancer Research Center; University of Lausanne; Lausanne, Switzerland.
authors.forename: Denarda
authors.initials: D
authors.lastname: Dangaj
authors.forename: Nathalie
authors.initials: N
authors.lastname: Scholler
keywords: B7-H4; cell surface expression; immunotherapy; ovarian cancer; recombinant antibodies; targeting